Policies to enhance the efficiency of prescribing in the Spanish Catalan region: impact and future direction

Expert Review of Pharmacoeconomics & Outcomes Research
Anna ComaAlan Haycox

Abstract

To assess the impact of recent national and regional initiatives on the utilization and expenditure of four high-volume classes to provide future guidance. These were proton pump inhibitors, statins and ezetimibe, and renin-angiotensin drugs, as well as newer antidepressants. An observational study of prescriptions dispensed in ambulatory care in Catalonia was conducted from 2003 to 2007. Utilization was converted into defined daily doses (DDDs) and DDDs per 1000 inhabitants per day, and compared over the study period, as well as with other European countries. As expected, there was increasing utilization of statins and renin-angiotensin drugs during the study period, as well as increased utilization of generics versus originators in each class; the latter figures were substantially greater than those published previously. There was also increased utilization of the proton pump inhibitors, which is a cause for concern. There were substantial reductions in the expenditure/DDDs of generics and originator products in 2007 versus 2003. For instance, expenditure/DDDs of generic and originator simvastatin were 81 and 72%, respectively, below 2003 originator prices. These reductions were much greater than those seen in previous public...Continue Reading

References

Dec 19, 2002·Biological Psychiatry·Stephen M StahlRichard L Rudolph
Jan 15, 2004·Health Policy·Jaume Puig-Junoy
Jan 27, 2004·Pharmacotherapy·Kristina S Yu-IsenbergAnn S M Harada
Feb 14, 2004·BMJ : British Medical Journal·Tom WalleyUNKNOWN EuroMedStat group
Dec 28, 2006·JAMA : the Journal of the American Medical Association·Yu-Xiao YangDavid C Metz
Apr 3, 2007·The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care·Fernando AntoñanzasCarmelo Juàrez
Apr 20, 2007·British Journal of Clinical Pharmacology·Solveig SakshaugSvetlana Skurtveit
May 19, 2007·The American Journal of Gastroenterology·Jennifer LeonardPaul Moayyedi
Jan 5, 2008·BMJ : British Medical Journal·Ian Forgacs, Aathavan Loganayagam
Apr 1, 2008·The New England Journal of Medicine·John J P KasteleinUNKNOWN ENHANCE Investigators
Apr 1, 2008·The New England Journal of Medicine·B Greg Brown, Allen J Taylor
Apr 16, 2008·QJM : Monthly Journal of the Association of Physicians·M N ChoudhryH M Ziglam
Apr 18, 2009·Expert Review of Pharmacoeconomics & Outcomes Research·Brian GodmanLars L Gustafsson
Apr 18, 2009·Basic & Clinical Pharmacology & Toxicology·Andreza Fabro de BemJoão Batista Teixeira Rocha
Apr 18, 2009·Basic & Clinical Pharmacology & Toxicology·Grzegorz Raszewski, Rafał Filip
Oct 6, 2009·Applied Health Economics and Health Policy·Björn WettermarkFlora M Haaijer-Ruskamp
Oct 13, 2009·Expert Review of Pharmacoeconomics & Outcomes Research·Brian GodmanPeter Wieninger

❮ Previous
Next ❯

Citations

May 10, 2013·European Journal of Clinical Pharmacology·Linda Björkhem-BergmanLars L Gustafsson
Dec 4, 2013·European Journal of Clinical Pharmacology·R Fernández UrrusunoB Pascual de la Pisa
Jan 5, 2014·Applied Health Economics and Health Policy·Ana Luísa Caires de SouzaLeonardo Maurício Diniz
Jun 12, 2013·Applied Health Economics and Health Policy·Brian GodmanLars L Gustafsson
Aug 13, 2011·Expert Review of Pharmacoeconomics & Outcomes Research·Luka VončinaLars L Gustafsson
Dec 10, 2014·Expert Review of Clinical Pharmacology·Brian GodmanLars L Gustafsson
Jul 21, 2012·Expert Review of Pharmacoeconomics & Outcomes Research·Ljiljana Sovic BrkicicMaja Relja
Nov 29, 2012·Expert Review of Pharmacoeconomics & Outcomes Research·Vanda Markovic-PekovicLars L Gustafsson
Feb 4, 2010·Expert Review of Pharmacoeconomics & Outcomes Research·Diane McGinnAlan Haycox
Feb 14, 2013·Expert Review of Pharmacoeconomics & Outcomes Research·Jessica FraeymanPhilippe Beutels
Dec 21, 2012·Expert Review of Pharmacoeconomics & Outcomes Research·Anna BucsicsRickard E Malmström
Apr 25, 2014·Expert Review of Pharmacoeconomics & Outcomes Research·Pieter DylstSteven Simoens
Jan 28, 2012·Expert Review of Pharmacoeconomics & Outcomes Research·Mohammed AbuelkhairLars L Gustafsson
Jun 16, 2011·Expert Review of Pharmacoeconomics & Outcomes Research·Kristina GaruolieneAlan Haycox
Apr 14, 2010·Expert Review of Pharmacoeconomics & Outcomes Research·Brian GodmanPeter Wieninger
Mar 1, 2011·Expert Review of Pharmacoeconomics & Outcomes Research·Brian GodmanAlan Haycox
Feb 13, 2014·Health Economics·Petros PechlivanoglouMaarten J Postma
Jan 7, 2015·Saudi Pharmaceutical Journal : SPJ : the Official Publication of the Saudi Pharmaceutical Society·Mohamed Azmi HassaliHisham Aljadhey
Oct 24, 2014·Frontiers in Pharmacology·James C MoonRickard E Malmström
Aug 16, 2016·Frontiers in Pharmacology·Winnie de BruijnBrian Godman
Dec 16, 2010·Expert Review of Pharmacoeconomics & Outcomes Research·Brian GodmanLars L Gustafsson

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.